Overview

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma. This study will include a screening visit followed by a 4 month treatment period.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Formoterol Fumarate